|Articles|October 2, 2022
- Pharmaceutical Technology, October 2022
- Volume 46
- Issue 10
- Pages: 12
Inorganic DNA Replication Enzyme
Author(s)Pharmaceutical Technology Editors
The new inorganic pyrophosphate from Canvax is intended for use in RNA IVT reactions.
Canvax’s new inorganic pyrophosphatase is a DNA replication enhancer with ≥ 95% purity and has an enhanced capacity for increasing RNA yield in in-vitro transcription (IVT) reactions. The enzyme, which is isolated from Escherichia coli, has demonstrated stability below 80ºF, and is free of endonucleases, exonucleases, and RNAases.
The enzyme is intended for use in RNA IVT reactions, as it is designed to reduce the inhibitory effects of protein-protein interactions. In addition, it is suitable for use in messenger RNA-based vaccine manufacturing, RNA labeling, and enhancement of DNA replication.
Articles in this issue
over 3 years ago
Adopting Smart Development Strategiesover 3 years ago
Reformulating Successover 3 years ago
Analyzing Extractables and Leachables in Single-Use Systemsover 3 years ago
Improving Sterility Using Blow-Fill-Seal Technologyover 3 years ago
Electrochemistry for API Synthesisover 3 years ago
Shining a Light on Lipid Nanoparticle Characterizationover 3 years ago
The Future of Drug Delivery for Biopharmaceuticalsover 3 years ago
The State of Contamination Controlover 3 years ago
Biologic Standards in the Pharmacopoeias: An UpdateNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
2
Women in STEM: Early Phase Drug Development
3
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B
4
PharmTech Weekly Roundup - February 6, 2026
5